Literature DB >> 24821177

Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors.

Zineb Lioussfi1, Zineb Errami, Aicha Radoui, Hakima Rhou, Fatima Ezzaitouni, Naima Ouzeddoun, Rabea Bayahia, Loubna Benamar.   

Abstract

The aim of this study is to investigate the prevalence of hepatitis C virus (HCV) and hepatitis B virus (HBV) in maintenance hemodialysis (HD) and continuous ambulatory peritoneal dialysis patients at the Rabat University Hospital and to identify the major risk factors for transmission. A retrospective study was performed in 67 chronic HD and 36 peritoneal dialysis patients. For the screening of viral infections, we tested for anti-HCV antibodies and HBs antigen (Hbs Ag). We compared infected and non-infected patients in order to determine the risk factors for contamination. In the HD unit, the prevalence of anti-HCV was 60% and the prevalence of HBs Ag was 6%. Duration of dialysis (P = 0.001) was the only risk factor in our HD patients. In peritoneal dialysis (PD), the prevalence of anti-HCV was 8%. Hbs Ag was detected in 2.6% of our PD patients. Viral hepatitis C is the main viral infection in our HD unit. The duration of dialysis is the main risk factor for infection in our study. The transmission is essentially nosocomial, requiring a strict adherence to infection control procedures.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24821177     DOI: 10.4103/1319-2442.132236

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  13 in total

Review 1.  Immune response to hepatitis B vaccine among patients on hemodialysis.

Authors:  Gasim I Gasim; Abdelhaleem Bella; Ishag Adam
Journal:  World J Hepatol       Date:  2015-02-27

2.  Factors affecting responsiveness to hepatitis B immunization in dialysis patients.

Authors:  Ali Asan; Huriye Demirhan; Hülya Çetin Sorkun; Sevgi Özkan; Mehtap Aydın; Davut Akın; Bengü Tatar; Binali Çatak; Alper Şener; Şükran Köse
Journal:  Int Urol Nephrol       Date:  2017-06-15       Impact factor: 2.370

3.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Infection       Date:  2018-09-25       Impact factor: 3.553

4.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  J Nephrol       Date:  2018-09-25       Impact factor: 3.902

5.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Intern Emerg Med       Date:  2018-09-25       Impact factor: 3.397

Review 6.  Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions.

Authors:  Manale Harfouche; Hiam Chemaitelly; Silva P Kouyoumjian; Sarwat Mahmud; Karima Chaabna; Zaina Al-Kanaani; Laith J Abu-Raddad
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

7.  Risk factors associated with nosocomial infections among end stage renal disease patients undergoing hemodialysis: A systematic review.

Authors:  Saad Hanif Abbasi; Raja Ahsan Aftab; Siew Siang Chua
Journal:  PLoS One       Date:  2020-06-22       Impact factor: 3.240

8.  Seroprevalence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among hemodialysis patients in a Tertiary Care Teaching Hospital in a developing country.

Authors:  Sonam Kansay; Jannat Sekhon; Saifi Rana
Journal:  Indian J Sex Transm Dis AIDS       Date:  2019 Jul-Dec

9.  Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient.

Authors:  Jin Chen; Yi Li; Guisen Li; Pu Lei
Journal:  Ren Fail       Date:  2020-11       Impact factor: 3.222

10.  The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis.

Authors:  Tiruneh Adane; Solomon Getawa
Journal:  PLoS One       Date:  2021-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.